New mass spec for Thermo

Thermo Fisher Scientific acquires Slovakian mass spec software firm HighChem
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN JOSE, Calif.—In June, Thermo Fisher Scientific acquired HighChem, a developer of mass spectrometry software based in Bratislava, Slovakia. Financial and other terms of the transaction were not disclosed. The company provides software that is used by pharmaceutical and metabolomics laboratories for analyzing complex data and identifying small molecules.
 
“Our customers rely on us to provide advanced software solutions that interpret data quickly and accurately to make compound identification simple and understandable,” said Mitch Kennedy, president of chromatography and mass spectrometry at Thermo Fisher Scientific. “The addition of HighChem’s software solutions to our existing mass spectrometry software portfolio will enable us to deliver greater value for our mass spectrometry customers.”
 
HighChem will be integrated into Thermo Fisher’s chromatography and mass spectrometry business, which is part of the firm’s Analytical Instruments unit.
 
As a leading provider of life-sciences technology globally, Thermo Fisher Scientific works to help customers accelerate research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Its premier brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Related Topics

Published In

Volume 15 - Issue 7 | July 2019

July 2019

July 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue